Amendments to the claims:

This listing of claims will replace all prior versions, and listing, of claims in the application:

Claims 1-14. (Cancelled).

15. (New) A compound, which is 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt, wherein said compound provides at least one of:

C2

(i) an infra red spectrum containing peaks at 1752, 1546, 1154, 621, and 602 cm^{-1};

(ii) a Raman spectrum containing peaks at 1751, 1243 and 602 cm^{-1};

(iii) a solid-state ^{13}C nuclear magnetic resonance spectrum containing peaks at 111.9, 114.8, 119.6, 129.2, 134.0, 138.0, 144.7, 153.2, 157.1, 170.7, 170.7, 172.0 and 175.0 ppm; and

(iv) an X-ray powder diffraction pattern which gives calculated lattice spacings of 6.46, 5.39, 4.83, 4.68, 3.71, 3.63, 3.58, and 3.48 Angstroms.

16. (New) A compound, which is 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt, wherein said compound provides each of:

(i) an infra red spectrum containing peaks at 1752, 1546, 1154, 621, and 602 cm^{-1};

(ii) a Raman spectrum containing peaks at 1751, 1243 and 602 cm^{-1};

(iii) a solid-state ^{13}C nuclear magnetic resonance spectrum containing peaks at 111.9, 114.8, 119.6, 129.2, 134.0, 138.0, 144.7, 153.2, 157.1, 170.7, 170.7, 172.0 and 175.0 ppm; and

(iv) an X-ray powder diffraction pattern which gives calculated lattice spacings of 6.46, 5.39, 4.83, 4.68, 3.71, 3.63, 3.58, and 3.48 Angstroms.

17. (New) A compound according to claim 15, which, in a mineral oil dispersion, provides an infra red spectrum substantially in accordance with Figure 1.

18. (New) A compound according to claim 15, which provides a Raman spectrum substantially in accordance with Figure II.

19. (New) A compound according to claim 15, which provides a solid-state ^{13}C nuclear magnetic resonance spectrum substantially in accordance with Figure III.

20. (New) A compound according to claim 15, which provides a solid-state ^{13}C nuclear magnetic resonance spectrum substantially in accordance with Table I.

C2

21. (New) A compound according to claim 15, which provides an X-ray powder diffraction pattern substantially in accordance with Figure IV.

22. (New) A compound according to claim 15, which provides an X-ray powder diffraction pattern substantially in accordance with Table II.

23. (New) A compound according to claim 15, in isolated form.

24. (New) A process for preparing the compound according to claim 15, comprising:

cooling a solution of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt in denatured ethanol from an elevated temperature to crystallize said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt, and

recovering said compound.

25. (New) A method for the treatment of diabetes mellitus, conditions associated with diabetes mellitus and complications thereof, in a human or non-human mammal which comprises administering an effective, non-toxic, amount of the compound according to any one of claims 15-23 to a human or non-human mammal in need thereof.

26. (New) A method for the treatment of Type II diabetes in a human or non-human mammal which comprises administering an effective, non-toxic, amount of the compound according to any one of claims 15-23 to a human or non-human mammal in need thereof.

27. (New) A pharmaceutical composition comprising an effective, non-toxic amount of the compound according to any one of claims 15-23 and a pharmaceutically acceptable carrier therefor.

28. (New) A pharmaceutical composition consisting essentially of an effective, non-toxic amount of the compound according to any one of claims 15-23 and a pharmaceutically acceptable carrier therefor.

C2

29. (New) A pharmaceutical composition according to claim 27, wherein said composition is adapted for oral administration.

30. (New) A pharmaceutical composition according to claim 29, wherein said composition is in the form of a tablet or a capsule.

31. (New) A pharmaceutical composition according to claim 28, wherein said composition is adapted for oral administration.

32. (New) A pharmaceutical composition according to claim 31, wherein said composition is in the form of a tablet or a capsule.

33. (New) A process for converting the compound according to claim 15 into a polymorph of said compound, comprising:

(a) seeding a solution of the compound according to claim 15 in a solvent with the polymorph of said compound;

(b) recovering the polymorph of the compound according to claim 15.

34. (New) A process according to claim 33, wherein said solvent is acetone or ethanol.

35. (New) A process according to claim 33, further comprising filtering the solution formed in step (a).

36. (New) A process according to claim 35, further comprising heating or concentrating said filtered solution.

C2

37. (New) A process according to claim 33, wherein the solution is cooled at a rate of about 1°C/min.

38. (New) A process according to claim 33, wherein the solution is seeded at a temperature of 50°C.